Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 2/20 | 0.33 |
| ▸ | CDK8 | P49336 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15833604 | 0.71 | MAPT (0.41) | ADORA2AADORA1ADORA3MAPTALDH1A1 | |
| SCHEMBL15819411 | 0.69 | ADORA2A (0.46) | ADORA2AADORA1ADORA3MAPTALDH1A1 | |
| SCHEMBL30876453 | 0.69 | CCR1 (0.45) | ADORA2AADORA1ADORA3MAPTALDH1A1 | |
| SCHEMBL19928112 | 0.68 | MAPT (0.39) | ADORA2AADORA1ADORA3MAPTALDH1A1 | |
| SCHEMBL25786732 | 0.67 | MAPT (0.38) | ADORA2AADORA1ADORA3MAPTALDH1A1 | |
| SCHEMBL19421522 | 0.67 | MAPT (0.38) | ADORA2AADORA1ADORA3MAPTALDH1A1 | |
| SCHEMBL31600322 | 0.67 | CYP1A2 (0.40) | ADORA2AADORA1ADORA3MAPTALDH1A1 | |
| SCHEMBL21604623 | 0.67 | MAPT (0.54) | MAPTALDH1A1KDM4ENSD2 | |
| SCHEMBL21604520 | 0.66 | MAPT (0.41) | ADORA2AADORA1MAPTALDH1A1KDM4E | |
| SCHEMBL25690528 | 0.66 | ADORA2A (0.39) | ADORA2AADORA1ADORA3ADORA2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | ADORA2A 3776/4885ADORA1 3753/4885ADORA3 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.